<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 30.4 - Haemolytic Anaemia [SDL]</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 30.4 - Haemolytic Anaemia [SDL] | MD3 SCP Cases">
  <meta name="description" content="Self-directed learning on haemolytic anaemia: classification, inherited vs acquired causes, G6PD deficiency, AIHA, MAHA (TTP/HUS), diagnostic approach, and management.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:title" content="Case 30.4 - Haemolytic Anaemia [SDL]">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="Self-directed learning on haemolytic anaemia: classification, inherited vs acquired causes, G6PD deficiency, AIHA, MAHA (TTP/HUS), diagnostic approach, and management.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 30.4 – Haemolytic Anaemia [SDL]</h1>
    <p class="meta"><strong>Category:</strong> Medicine | <strong>Discipline:</strong> Haematology | <strong>Week:</strong> 30</p>

    <h2>Self-Directed Learning Overview</h2>
    <p>This self-directed learning case focuses on <strong>Haemolytic Anaemia</strong>, a diverse group of conditions characterized by premature destruction of red blood cells (RBCs), leading to shortened RBC survival (<120 days). Understanding haemolysis is essential as it can range from chronic compensated anaemia to acute life-threatening emergencies.</p>

    <h2>Learning Objectives</h2>
    <p>By the end of this SDL session, you should be able to:</p>
    <ul>
      <li>Define haemolytic anaemia and explain the underlying pathophysiology</li>
      <li>Recognize the clinical features and laboratory findings of haemolysis</li>
      <li>Classify haemolytic anaemias (inherited vs acquired, intravascular vs extravascular)</li>
      <li>Understand the major inherited haemolytic anaemias (G6PD deficiency, hereditary spherocytosis, sickle cell disease, thalassaemia)</li>
      <li>Understand the major acquired haemolytic anaemias (autoimmune, microangiopathic, PNH)</li>
      <li>Interpret investigations including blood film, reticulocyte count, LDH, haptoglobin, and direct antiglobulin test (DAT/Coombs)</li>
      <li>Outline the management principles for different types of haemolytic anaemia</li>
    </ul>

    <h2>Case Scenario</h2>
    <p>Mr. David Chen, a 28-year-old man of Mediterranean descent, presents to the Emergency Department with a 2-day history of dark urine, jaundice, and fatigue. He had been feeling unwell for the past week with an upper respiratory tract infection and started taking antibiotics (co-trimoxazole) 3 days ago. He denies any previous episodes of jaundice but mentions his father had "some blood problem" requiring splenectomy.</p>

    <div class="vital-signs">
      <strong>On Examination:</strong>
      <ul>
        <li>General: Jaundiced, appears unwell but not in distress</li>
        <li>Temperature: 37.2°C, Heart rate: 102 bpm, BP: 128/76 mmHg, RR: 16/min, SpO₂: 98% on air</li>
        <li>Eyes: Scleral icterus, mild conjunctival pallor</li>
        <li>Cardiovascular: Tachycardic, no murmurs</li>
        <li>Respiratory: Clear chest</li>
        <li>Abdomen: Soft, mild splenomegaly palpable 2cm below left costal margin, no hepatomegaly, no tenderness</li>
        <li>Skin: Jaundice, no rash, no petechiae</li>
      </ul>
    </div>

    <h2>Initial Investigations</h2>
    <div class="investigation-results">
      <strong>Full Blood Count:</strong>
      <ul>
        <li>Hb: 78 g/L (normal 130-180 g/L for men) - Anaemia</li>
        <li>MCV: 88 fL (normal 80-100 fL) - Normocytic</li>
        <li>WCC: 11.2 × 10⁹/L (normal 4-11 × 10⁹/L)</li>
        <li>Platelets: 268 × 10⁹/L (normal 150-400 × 10⁹/L)</li>
        <li><strong>Reticulocytes: 18%</strong> (normal 0.5-2.5%) - <strong>Elevated (indicates marrow response to haemolysis)</strong></li>
      </ul>
      <strong>Blood Film:</strong> Normocytic anaemia with polychromasia (young RBCs), occasional bite cells, blister cells. No spherocytes. No fragmented cells (schistocytes).
      <br><br>
      <strong>Biochemistry:</strong>
      <ul>
        <li><strong>Bilirubin: 68 μmol/L</strong> (normal 3-17 μmol/L) - predominantly unconjugated (58 μmol/L)</li>
        <li><strong>LDH: 1250 U/L</strong> (normal 100-250 U/L) - markedly elevated</li>
        <li><strong>Haptoglobin: <0.1 g/L</strong> (normal 0.3-2.0 g/L) - undetectable</li>
        <li>AST: 42 U/L, ALT: 38 U/L (mildly elevated)</li>
        <li>Creatinine: 88 μmol/L (normal)</li>
      </ul>
      <strong>Urine:</strong> Dark urine, dipstick shows blood ++ (haemoglobinuria), no RBCs on microscopy, urobilinogen ++
      <br><br>
      <strong>Direct Antiglobulin Test (DAT/Coombs):</strong> Negative
    </div>

    <h2>Key Topics to Explore</h2>

    <div class="question">
      <h3>1. Definition and Pathophysiology of Haemolysis</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Definition:</strong></p>
        <p>Haemolytic anaemia occurs when red blood cells are destroyed prematurely (normal RBC lifespan is 120 days). The bone marrow compensates by increasing RBC production (reticulocytosis), but if destruction exceeds production, anaemia develops.</p>

        <p><strong>Types of Haemolysis by Location:</strong></p>

        <table>
          <tr>
            <th>Type</th>
            <th>Location</th>
            <th>Mechanism</th>
            <th>Features</th>
          </tr>
          <tr>
            <td><strong>Extravascular Haemolysis</strong></td>
            <td>Reticuloendothelial system<br>(spleen, liver, bone marrow)</td>
            <td>
              Macrophages phagocytose abnormal/damaged RBCs
            </td>
            <td>
              <ul>
                <li>Anaemia, jaundice, splenomegaly</li>
                <li>↑ Unconjugated bilirubin</li>
                <li>↑ Urobilinogen in urine</li>
                <li>Normal/low haptoglobin</li>
                <li>No haemoglobinuria</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Intravascular Haemolysis</strong></td>
            <td>Within blood vessels</td>
            <td>
              Direct RBC destruction releasing free haemoglobin into plasma
            </td>
            <td>
              <ul>
                <li>All features of extravascular PLUS:</li>
                <li>↑↑ LDH (very high)</li>
                <li><strong>Undetectable haptoglobin</strong> (binds free Hb)</li>
                <li><strong>Haemoglobinuria</strong> (dark urine)</li>
                <li>Haemoglobinaemia (pink plasma)</li>
                <li>Methaemalbuminaemia</li>
              </ul>
            </td>
          </tr>
        </table>

        <p><strong>Pathophysiology - Compensatory Response:</strong></p>
        <ul>
          <li><strong>Bone marrow response:</strong> Erythroid hyperplasia, reticulocytosis (up to 6-8x normal production)</li>
          <li><strong>Compensated haemolysis:</strong> Increased destruction balanced by increased production → no anaemia but elevated bilirubin and reticulocytes</li>
          <li><strong>Decompensated haemolysis:</strong> Destruction exceeds production → anaemia develops</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>2. Clinical Features of Haemolysis</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Symptoms:</strong></p>
        <ul>
          <li><strong>Anaemia symptoms:</strong> Fatigue, weakness, dyspnoea, palpitations, dizziness</li>
          <li><strong>Jaundice:</strong> Yellow discoloration of skin and sclera (unconjugated hyperbilirubinaemia)</li>
          <li><strong>Dark urine:</strong> Due to excess urobilinogen (extravascular) or haemoglobinuria (intravascular)</li>
          <li><strong>Abdominal pain:</strong> Splenic infarction (sickle cell), gallstones</li>
          <li><strong>Acute symptoms:</strong> In acute haemolysis - rigors, fever, back pain, collapse</li>
        </ul>

        <p><strong>Signs:</strong></p>
        <ul>
          <li><strong>Pallor:</strong> Conjunctival and skin pallor</li>
          <li><strong>Jaundice:</strong> Scleral icterus, skin jaundice</li>
          <li><strong>Splenomegaly:</strong> Common in chronic haemolysis (site of RBC destruction)</li>
          <li><strong>Hepatomegaly:</strong> May occur with chronic haemolysis</li>
          <li><strong>Leg ulcers:</strong> Chronic haemolysis (sickle cell disease)</li>
          <li><strong>Gallstones:</strong> Pigment stones from chronic bilirubin production</li>
        </ul>

        <p><strong>Special Clinical Syndromes:</strong></p>
        <table>
          <tr>
            <th>Syndrome</th>
            <th>Features</th>
          </tr>
          <tr>
            <td><strong>Haemolytic Crisis</strong></td>
            <td>Acute drop in Hb, jaundice, dark urine, rigors, fever - requires urgent treatment</td>
          </tr>
          <tr>
            <td><strong>Aplastic Crisis</strong></td>
            <td>
              Sudden cessation of RBC production (usually parvovirus B19 infection) in chronic haemolytic anaemia.
              Severe anaemia with LOW reticulocytes (paradoxical). Life-threatening.
            </td>
          </tr>
          <tr>
            <td><strong>Sequestration Crisis</strong></td>
            <td>Sudden splenic enlargement trapping RBCs (mainly sickle cell disease in children). Hypovolaemic shock.</td>
          </tr>
        </table>
      </div>
    </div>

    <div class="question">
      <h3>3. Laboratory Diagnosis of Haemolysis</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>General Markers of Haemolysis:</strong></p>

        <table>
          <tr>
            <th>Investigation</th>
            <th>Finding in Haemolysis</th>
            <th>Explanation</th>
          </tr>
          <tr>
            <td><strong>Reticulocyte Count</strong></td>
            <td>↑↑ Elevated (often >2%)</td>
            <td>Bone marrow compensation - young RBCs released early. <strong>MOST IMPORTANT TEST.</strong> Exception: Aplastic crisis (low reticulocytes)</td>
          </tr>
          <tr>
            <td><strong>Bilirubin</strong></td>
            <td>↑ Unconjugated</td>
            <td>Breakdown product of haem from destroyed RBCs</td>
          </tr>
          <tr>
            <td><strong>LDH</strong></td>
            <td>↑↑ Elevated</td>
            <td>Released from destroyed RBCs. Very high in intravascular haemolysis</td>
          </tr>
          <tr>
            <td><strong>Haptoglobin</strong></td>
            <td>↓ Low/undetectable</td>
            <td>Binds free haemoglobin. <strong>Undetectable = intravascular haemolysis</strong></td>
          </tr>
          <tr>
            <td><strong>Blood Film</strong></td>
            <td>Polychromasia, specific abnormalities</td>
            <td>
              Polychromasia = reticulocytes (blue-purple colour).
              Plus specific features: spherocytes, schistocytes, sickle cells, etc.
            </td>
          </tr>
          <tr>
            <td><strong>Urinalysis</strong></td>
            <td>
              ↑ Urobilinogen (extravascular)<br>
              Haemoglobinuria (intravascular)
            </td>
            <td>
              Urobilinogen: bilirubin conjugated in liver, converted by gut bacteria<br>
              Haemoglobinuria: free Hb filtered by kidneys (dipstick +ve for blood, no RBCs on microscopy)
            </td>
          </tr>
        </table>

        <p><strong>Specific Tests to Identify Cause:</strong></p>
        <ul>
          <li><strong>Direct Antiglobulin Test (DAT/Coombs Test):</strong>
            <ul>
              <li>Detects antibodies or complement bound to RBC surface</li>
              <li><strong>Positive</strong> = Autoimmune haemolytic anaemia (AIHA), drug-induced, haemolytic transfusion reaction</li>
              <li><strong>Negative</strong> = Non-immune causes (hereditary, mechanical, PNH, etc.)</li>
            </ul>
          </li>
          <li><strong>Blood Film:</strong> Specific RBC morphology points to cause (see classification section)</li>
          <li><strong>Haemoglobin Electrophoresis:</strong> Sickle cell disease, thalassaemia</li>
          <li><strong>Enzyme Assays:</strong> G6PD, pyruvate kinase deficiency</li>
          <li><strong>Osmotic Fragility Test:</strong> Hereditary spherocytosis</li>
          <li><strong>Flow Cytometry:</strong> PNH (CD55/CD59 deficiency)</li>
          <li><strong>Cold Agglutinins:</strong> Cold AIHA</li>
        </ul>

        <p><strong>Diagnostic Algorithm:</strong></p>
        <pre>
Suspected Haemolysis (anaemia + jaundice ± splenomegaly)
        ↓
Confirm Haemolysis: ↑ Reticulocytes, ↑ Bilirubin (unconj), ↑ LDH, ↓ Haptoglobin
        ↓
Blood Film + DAT (Coombs Test)
        ↓
    DAT Positive → AIHA, Drug-induced
        ↓
    DAT Negative → Check Blood Film
        ↓
        Spherocytes → Hereditary Spherocytosis
        Sickle cells → Sickle Cell Disease
        Target cells → Thalassaemia
        Bite/Blister cells → G6PD deficiency
        Schistocytes (fragmented RBCs) → Microangiopathic (TTP, HUS, DIC, mechanical valves)
        Normal morphology → Consider PNH, enzyme defects
        </pre>
      </div>
    </div>

    <div class="question">
      <h3>4. Classification of Haemolytic Anaemias</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>INHERITED (Intrinsic RBC Defects):</strong></p>

        <table>
          <tr>
            <th>Category</th>
            <th>Condition</th>
            <th>Key Features</th>
          </tr>
          <tr>
            <td rowspan="2"><strong>Membrane Defects</strong></td>
            <td><strong>Hereditary Spherocytosis</strong></td>
            <td>
              AD inheritance, spherocytes on film, splenomegaly, ↑ MCHC, osmotic fragility test +ve.
              Treatment: Splenectomy curative
            </td>
          </tr>
          <tr>
            <td><strong>Hereditary Elliptocytosis</strong></td>
            <td>Elliptical RBCs, usually mild or asymptomatic</td>
          </tr>
          <tr>
            <td rowspan="2"><strong>Enzyme Defects</strong></td>
            <td><strong>G6PD Deficiency</strong></td>
            <td>
              X-linked recessive (males affected), Mediterranean/African/Asian descent.
              Episodic haemolysis triggered by infection, drugs (antimalarials, sulfonamides), fava beans.
              Blood film: Bite cells, blister cells, Heinz bodies.
              Intravascular haemolysis.
              Diagnosis: G6PD enzyme assay (do AFTER acute episode)
            </td>
          </tr>
          <tr>
            <td><strong>Pyruvate Kinase Deficiency</strong></td>
            <td>AR inheritance, chronic haemolysis, splenomegaly</td>
          </tr>
          <tr>
            <td rowspan="2"><strong>Haemoglobinopathies</strong></td>
            <td><strong>Sickle Cell Disease</strong></td>
            <td>
              HbSS (homozygous), sickle cells on film, vaso-occlusive crises, acute chest syndrome, stroke risk.
              Diagnosis: Hb electrophoresis.
              Management: Hydroxycarbamide, vaccinations, penicillin prophylaxis, transfusions
            </td>
          </tr>
          <tr>
            <td><strong>Thalassaemia</strong></td>
            <td>
              α or β thalassaemia. Microcytic anaemia, target cells, splenomegaly.
              β-thalassaemia major: transfusion-dependent, iron overload.
              Diagnosis: Hb electrophoresis, ↑ HbA₂ in β-thal trait
            </td>
          </tr>
        </table>

        <p><strong>ACQUIRED (Extrinsic to RBC):</strong></p>

        <table>
          <tr>
            <th>Category</th>
            <th>Condition</th>
            <th>Key Features</th>
          </tr>
          <tr>
            <td rowspan="3"><strong>Immune-Mediated</strong></td>
            <td><strong>Warm AIHA</strong></td>
            <td>
              IgG antibodies, optimal at 37°C. DAT +ve. Spherocytes on film.
              Causes: Idiopathic (50%), SLE, lymphoma, CLL, drugs (methyldopa, penicillin).
              Treatment: Steroids, rituximab, splenectomy
            </td>
          </tr>
          <tr>
            <td><strong>Cold AIHA</strong></td>
            <td>
              IgM antibodies, optimal at 4°C. Agglutination in cold. Acrocyanosis.
              Causes: Idiopathic, Mycoplasma, EBV, lymphoma.
              Treatment: Avoid cold, rituximab. <strong>Steroids NOT effective</strong>
            </td>
          </tr>
          <tr>
            <td><strong>Drug-Induced</strong></td>
            <td>
              Penicillin, methyldopa, cephalosporins, quinine. DAT +ve. Stop drug.
            </td>
          </tr>
          <tr>
            <td rowspan="4"><strong>Mechanical/Microangiopathic</strong></td>
            <td><strong>TTP (Thrombotic Thrombocytopenic Purpura)</strong></td>
            <td>
              Pentad: MAHA + Thrombocytopenia + AKI + Neuro signs + Fever.
              Schistocytes on film. ADAMTS13 deficiency.
              Treatment: <strong>URGENT plasma exchange</strong>
            </td>
          </tr>
          <tr>
            <td><strong>HUS (Haemolytic Uraemic Syndrome)</strong></td>
            <td>
              Triad: MAHA + Thrombocytopenia + AKI. Often post-diarrhoea (E. coli O157:H7).
              Schistocytes. Treatment: Supportive ± eculizumab (atypical HUS)
            </td>
          </tr>
          <tr>
            <td><strong>DIC</strong></td>
            <td>
              Consumption of clotting factors. ↓ Platelets, ↓ Fibrinogen, ↑ PT/APTT, ↑ D-dimer, schistocytes.
              Treatment: Treat underlying cause
            </td>
          </tr>
          <tr>
            <td><strong>Mechanical Valves</strong></td>
            <td>Chronic low-grade haemolysis, schistocytes</td>
          </tr>
          <tr>
            <td><strong>Infections</strong></td>
            <td><strong>Malaria</strong></td>
            <td>
              <em>Plasmodium</em> parasites visible within RBCs on thick/thin blood films.
              Severe falciparum malaria: intravascular haemolysis, blackwater fever
            </td>
          </tr>
          <tr>
            <td><strong>Other</strong></td>
            <td><strong>PNH (Paroxysmal Nocturnal Haemoglobinuria)</strong></td>
            <td>
              Acquired stem cell disorder. Intravascular haemolysis, dark urine (morning), thrombosis, pancytopenia.
              Flow cytometry: CD55/CD59 deficiency. DAT negative.
              Treatment: Eculizumab (complement inhibitor)
            </td>
          </tr>
        </table>
      </div>
    </div>

    <div class="question">
      <h3>5. G6PD Deficiency - Detailed Review</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency</strong> is the most common inherited enzyme defect affecting red blood cells, and is highly relevant to this case scenario.</p>

        <p><strong>Genetics and Epidemiology:</strong></p>
        <ul>
          <li><strong>X-linked recessive</strong> inheritance (males affected, females carriers but can have symptoms due to lyonization)</li>
          <li>Prevalent in Mediterranean, African, Middle Eastern, and Asian populations</li>
          <li>Provides protection against malaria (evolutionary advantage)</li>
          <li>Affects >400 million people worldwide</li>
        </ul>

        <p><strong>Pathophysiology:</strong></p>
        <ul>
          <li>G6PD is essential for pentose phosphate pathway</li>
          <li>Generates NADPH, which protects RBCs from oxidative damage by maintaining reduced glutathione</li>
          <li>G6PD deficiency → reduced NADPH → oxidative stress → haemoglobin precipitation (Heinz bodies) → membrane damage → haemolysis</li>
          <li>Older RBCs most affected (lower G6PD activity)</li>
        </ul>

        <p><strong>Clinical Features:</strong></p>
        <ul>
          <li><strong>Usually asymptomatic</strong> between episodes</li>
          <li><strong>Episodic acute haemolysis</strong> triggered by oxidative stress:
            <ul>
              <li><strong>Infections:</strong> Most common trigger (viral/bacterial URTI, UTI)</li>
              <li><strong>Drugs:</strong> Antimalarials (primaquine), sulfonamides (co-trimoxazole), nitrofurantoin, aspirin (high dose), dapsone, rasburicase</li>
              <li><strong>Fava beans</strong> (broad beans) - hence "favism"</li>
              <li>Diabetic ketoacidosis</li>
            </ul>
          </li>
          <li><strong>Neonatal jaundice:</strong> Can cause severe hyperbilirubinaemia in newborns (risk of kernicterus)</li>
        </ul>

        <p><strong>Acute Haemolytic Episode Features:</strong></p>
        <ul>
          <li>Onset 24-72 hours after trigger exposure</li>
          <li>Jaundice, dark urine (haemoglobinuria), pallor</li>
          <li>Fatigue, dyspnoea, back pain</li>
          <li><strong>Intravascular haemolysis</strong> (undetectable haptoglobin, haemoglobinuria)</li>
          <li>Self-limiting if trigger removed</li>
        </ul>

        <p><strong>Blood Film Findings:</strong></p>
        <ul>
          <li><strong>Bite cells:</strong> RBCs with semicircular "bites" removed (macrophages remove Heinz bodies)</li>
          <li><strong>Blister cells:</strong> RBCs with hemoglobin pushed to one side</li>
          <li><strong>Heinz bodies:</strong> Precipitated denatured haemoglobin (requires supravital stain - not visible on routine films)</li>
          <li>Polychromasia (reticulocytosis)</li>
        </ul>

        <p><strong>Diagnosis:</strong></p>
        <ul>
          <li><strong>G6PD enzyme assay:</strong> Definitive test
            <ul>
              <li><strong>IMPORTANT:</strong> May be falsely normal during acute haemolysis (young RBCs have higher G6PD). Repeat 2-3 months after acute episode</li>
            </ul>
          </li>
          <li>Blood film: Bite cells, blister cells</li>
          <li>Heinz body stain (supravital staining)</li>
        </ul>

        <p><strong>Management:</strong></p>
        <ul>
          <li><strong>Acute Episode:</strong>
            <ul>
              <li><strong>Stop trigger</strong> (discontinue offending drug)</li>
              <li>Supportive care: Hydration (protect kidneys from free Hb), monitor Hb</li>
              <li>Transfusion if severe anaemia (Hb <70 g/L or symptomatic)</li>
              <li>Folic acid supplementation during acute haemolysis</li>
            </ul>
          </li>
          <li><strong>Long-term:</strong>
            <ul>
              <li><strong>Avoidance of triggers</strong> (education crucial - provide list of drugs/foods to avoid)</li>
              <li>Medical alert bracelet</li>
              <li>Screen family members (genetic counseling)</li>
              <li>Prophylactic folic acid not routinely needed</li>
            </ul>
          </li>
          <li><strong>Neonatal G6PD deficiency:</strong> Phototherapy ± exchange transfusion for severe jaundice</li>
        </ul>

        <p><strong>Prognosis:</strong></p>
        <ul>
          <li>Excellent with trigger avoidance</li>
          <li>Acute episodes self-limiting if trigger removed</li>
          <li>No long-term complications if managed appropriately</li>
        </ul>

        <p><strong>Drugs to AVOID in G6PD Deficiency:</strong></p>
        <table>
          <tr>
            <th>Drug Class</th>
            <th>Examples</th>
          </tr>
          <tr>
            <td>Antimalarials</td>
            <td>Primaquine, chloroquine (in some variants)</td>
          </tr>
          <tr>
            <td>Antibiotics</td>
            <td>Sulfonamides (co-trimoxazole, sulfasalazine), Nitrofurantoin, Quinolones (ciprofloxacin - debated)</td>
          </tr>
          <tr>
            <td>Analgesics</td>
            <td>Aspirin (high dose)</td>
          </tr>
          <tr>
            <td>Others</td>
            <td>Dapsone, Rasburicase, Methylene blue, Vitamin K analogues (in some variants)</td>
          </tr>
        </table>
      </div>
    </div>

    <div class="question">
      <h3>6. Autoimmune Haemolytic Anaemia (AIHA)</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>AIHA</strong> occurs when antibodies are directed against RBC surface antigens, leading to premature destruction.</p>

        <p><strong>Classification:</strong></p>

        <table>
          <tr>
            <th>Feature</th>
            <th>Warm AIHA</th>
            <th>Cold AIHA</th>
          </tr>
          <tr>
            <td><strong>Antibody Type</strong></td>
            <td>IgG (rarely IgA)</td>
            <td>IgM</td>
          </tr>
          <tr>
            <td><strong>Optimal Temperature</strong></td>
            <td>37°C (body temperature)</td>
            <td>4°C (cold)</td>
          </tr>
          <tr>
            <td><strong>Frequency</strong></td>
            <td>80-90% of AIHA cases</td>
            <td>10-20% of AIHA cases</td>
          </tr>
          <tr>
            <td><strong>Site of Haemolysis</strong></td>
            <td>Extravascular (spleen predominantly)</td>
            <td>Intravascular (complement activation) or extravascular (liver)</td>
          </tr>
          <tr>
            <td><strong>Blood Film</strong></td>
            <td>Spherocytes, polychromasia</td>
            <td>RBC agglutination (clumping), polychromasia</td>
          </tr>
          <tr>
            <td><strong>DAT (Coombs)</strong></td>
            <td>+ve for IgG ± complement (C3d)</td>
            <td>+ve for complement (C3d) only</td>
          </tr>
          <tr>
            <td><strong>Clinical Features</strong></td>
            <td>
              Anaemia, jaundice, splenomegaly.
              Gradual or acute onset
            </td>
            <td>
              Anaemia, jaundice, <strong>acrocyanosis</strong> (blue fingers/toes/ears in cold).
              Raynaud's phenomenon.
              Haemoglobinuria after cold exposure
            </td>
          </tr>
          <tr>
            <td><strong>Causes</strong></td>
            <td>
              <strong>Idiopathic (50%)</strong><br>
              Lymphoproliferative: CLL, lymphoma<br>
              Autoimmune: SLE<br>
              Drugs: Methyldopa, penicillin, cephalosporins<br>
              Infections: HIV
            </td>
            <td>
              <strong>Idiopathic (50%)</strong><br>
              Infections: <strong>Mycoplasma pneumoniae</strong>, EBV, CMV<br>
              Lymphoproliferative disorders<br>
              Cold agglutinin disease
            </td>
          </tr>
          <tr>
            <td><strong>Treatment</strong></td>
            <td>
              <strong>1st line: Prednisolone 1mg/kg</strong><br>
              2nd line: Rituximab (anti-CD20)<br>
              3rd line: Splenectomy<br>
              Other: Azathioprine, cyclophosphamide<br>
              Transfusion if severe (use least incompatible blood)
            </td>
            <td>
              <strong>Avoid cold exposure</strong> (keep warm)<br>
              <strong>Rituximab</strong> (effective)<br>
              <strong>Steroids NOT effective</strong><br>
              Treat underlying infection<br>
              Chlorambucil, cyclophosphamide (if severe)
            </td>
          </tr>
        </table>

        <p><strong>Direct Antiglobulin Test (DAT/Coombs Test):</strong></p>
        <ul>
          <li>Detects antibodies or complement bound to patient's RBCs</li>
          <li><strong>Positive in AIHA</strong> (warm and cold)</li>
          <li>Warm AIHA: +ve for IgG ± C3d</li>
          <li>Cold AIHA: +ve for C3d only (IgM dissociates at 37°C during washing)</li>
        </ul>

        <p><strong>Management Principles:</strong></p>
        <ul>
          <li><strong>Identify and treat underlying cause</strong> (stop drug, treat infection, treat lymphoma/SLE)</li>
          <li>Folic acid supplementation (ongoing haemolysis)</li>
          <li>Transfusion challenging - difficult crossmatch. Use "least incompatible" blood. Transfuse only if life-threatening</li>
          <li>Monitor for complications: gallstones, folate deficiency</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>7. Microangiopathic Haemolytic Anaemia (MAHA)</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>MAHA</strong> is a form of intravascular haemolysis caused by mechanical destruction of RBCs as they pass through damaged/abnormal microvasculature.</p>

        <p><strong>Pathophysiology:</strong></p>
        <ul>
          <li>RBCs sheared and fragmented as they pass through fibrin strands or damaged endothelium in small vessels</li>
          <li>Results in <strong>schistocytes (fragmented RBCs, helmet cells)</strong> on blood film - hallmark finding</li>
          <li>Intravascular haemolysis</li>
        </ul>

        <p><strong>Causes of MAHA:</strong></p>

        <table>
          <tr>
            <th>Condition</th>
            <th>Key Features</th>
          </tr>
          <tr>
            <td><strong>TTP<br>(Thrombotic Thrombocytopenic Purpura)</strong></td>
            <td>
              <strong>Classic Pentad (only 40% have all 5):</strong>
              <ul>
                <li>Microangiopathic haemolytic anaemia (MAHA)</li>
                <li>Thrombocytopenia (often severe <30)</li>
                <li>Acute kidney injury</li>
                <li>Neurological signs (confusion, seizures, stroke, fluctuating)</li>
                <li>Fever</li>
              </ul>
              <strong>Pathophysiology:</strong> ADAMTS13 deficiency (enzyme that cleaves von Willebrand factor) → ultra-large vWF multimers → platelet aggregation → microthrombi<br>
              <strong>Diagnosis:</strong> MAHA + thrombocytopenia + low ADAMTS13 activity (<10%)<br>
              <strong>Treatment:</strong> <strong>URGENT PLASMA EXCHANGE</strong> (do NOT wait for ADAMTS13 result). Steroids, rituximab. Avoid platelet transfusions (worsens thrombosis)
            </td>
          </tr>
          <tr>
            <td><strong>HUS<br>(Haemolytic Uraemic Syndrome)</strong></td>
            <td>
              <strong>Triad:</strong>
              <ul>
                <li>MAHA</li>
                <li>Thrombocytopenia (usually mild-moderate)</li>
                <li>Acute kidney injury (predominant feature)</li>
              </ul>
              <strong>Types:</strong>
              <ul>
                <li><strong>Typical HUS (90%):</strong> Post-diarrhoeal, <em>E. coli</em> O157:H7 (Shiga toxin), children. Self-limiting in many cases</li>
                <li><strong>Atypical HUS (10%):</strong> Complement dysregulation, any age, poorer prognosis</li>
              </ul>
              <strong>Treatment:</strong> Supportive (fluids, dialysis), eculizumab for atypical HUS
            </td>
          </tr>
          <tr>
            <td><strong>DIC<br>(Disseminated Intravascular Coagulation)</strong></td>
            <td>
              Consumption of clotting factors AND platelets → bleeding + thrombosis<br>
              <strong>Labs:</strong> ↓ Platelets, ↓ Fibrinogen, ↑ PT/APTT, ↑↑ D-dimer, schistocytes<br>
              <strong>Causes:</strong> Sepsis, trauma, malignancy, obstetric (placental abruption, amniotic fluid embolism)<br>
              <strong>Treatment:</strong> Treat underlying cause, supportive (FFP, platelets, cryoprecipitate)
            </td>
          </tr>
          <tr>
            <td><strong>Pre-eclampsia/HELLP Syndrome</strong></td>
            <td>
              <strong>HELLP:</strong> Haemolysis, Elevated Liver enzymes, Low Platelets<br>
              Pregnancy complication, maternal emergency<br>
              <strong>Treatment:</strong> Delivery of baby, supportive care
            </td>
          </tr>
          <tr>
            <td><strong>Mechanical Heart Valves</strong></td>
            <td>
              Chronic low-grade haemolysis<br>
              Schistocytes on film<br>
              Usually compensated, rarely requires treatment
            </td>
          </tr>
          <tr>
            <td><strong>Malignant Hypertension</strong></td>
            <td>Severe hypertension with end-organ damage, MAHA</td>
          </tr>
        </table>

        <p><strong>Key Diagnostic Feature:</strong></p>
        <ul>
          <li><strong>Schistocytes (fragmented RBCs) on blood film</strong> - essential for diagnosis</li>
          <li>Other names: Helmet cells, triangular cells, fragmented RBCs</li>
        </ul>

        <p><strong>Distinguishing TTP vs HUS:</strong></p>
        <table>
          <tr>
            <th>Feature</th>
            <th>TTP</th>
            <th>HUS</th>
          </tr>
          <tr>
            <td>Predominant organ</td>
            <td>Brain (neuro signs)</td>
            <td>Kidney (AKI)</td>
          </tr>
          <tr>
            <td>Age</td>
            <td>Adults (20-50 years)</td>
            <td>Children (typical HUS)</td>
          </tr>
          <tr>
            <td>Diarrhoea prodrome</td>
            <td>Rare</td>
            <td>Common (typical HUS - <em>E. coli</em>)</td>
          </tr>
          <tr>
            <td>ADAMTS13</td>
            <td>Severely deficient (<10%)</td>
            <td>Normal or mildly reduced</td>
          </tr>
          <tr>
            <td>Treatment</td>
            <td>URGENT plasma exchange</td>
            <td>Supportive ± eculizumab (atypical)</td>
          </tr>
        </table>
      </div>
    </div>

    <div class="question">
      <h3>8. Management Principles for Haemolytic Anaemia</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>General Management Approach:</strong></p>

        <p><strong>1. Acute Management:</strong></p>
        <ul>
          <li><strong>Assess severity:</strong> Check Hb, reticulocytes, signs of decompensation</li>
          <li><strong>Identify and treat underlying cause:</strong>
            <ul>
              <li>Stop offending drug (G6PD, drug-induced AIHA)</li>
              <li>Treat infection (malaria, Mycoplasma)</li>
              <li>Immunosuppression (AIHA)</li>
              <li>Urgent plasma exchange (TTP)</li>
            </ul>
          </li>
          <li><strong>Supportive care:</strong>
            <ul>
              <li><strong>Hydration:</strong> Especially important in intravascular haemolysis (protect kidneys from free Hb)</li>
              <li><strong>Folic acid 5mg daily:</strong> Increased demand due to RBC turnover</li>
              <li><strong>Transfusion:</strong> Only if severe symptomatic anaemia or Hb <70 g/L
                <ul>
                  <li>AIHA: Difficult crossmatch - use "least incompatible" blood</li>
                  <li>Avoid in TTP (worsens thrombosis if platelet transfusion)</li>
                </ul>
              </li>
            </ul>
          </li>
        </ul>

        <p><strong>2. Specific Treatments by Cause:</strong></p>
        <table>
          <tr>
            <th>Condition</th>
            <th>Specific Treatment</th>
          </tr>
          <tr>
            <td>G6PD Deficiency</td>
            <td>Stop trigger, hydration, transfusion if severe. Long-term: Avoidance education</td>
          </tr>
          <tr>
            <td>Hereditary Spherocytosis</td>
            <td>Folic acid. Splenectomy (curative, delay until >6 years). Vaccinations pre-splenectomy</td>
          </tr>
          <tr>
            <td>Sickle Cell Disease</td>
            <td>
              Hydroxycarbamide (↑ HbF), penicillin prophylaxis, vaccinations, analgesia for crises,
              exchange transfusion for acute chest/stroke, bone marrow transplant (curative)
            </td>
          </tr>
          <tr>
            <td>Warm AIHA</td>
            <td>Prednisolone 1mg/kg → Rituximab → Splenectomy. Treat underlying cause</td>
          </tr>
          <tr>
            <td>Cold AIHA</td>
            <td>Keep warm, Rituximab. <strong>Steroids NOT effective</strong></td>
          </tr>
          <tr>
            <td>TTP</td>
            <td><strong>URGENT plasma exchange</strong>, steroids, rituximab. Avoid platelet transfusion</td>
          </tr>
          <tr>
            <td>HUS (typical)</td>
            <td>Supportive (fluids, dialysis). Avoid antibiotics (may worsen toxin release)</td>
          </tr>
          <tr>
            <td>HUS (atypical)</td>
            <td>Eculizumab (complement inhibitor)</td>
          </tr>
          <tr>
            <td>PNH</td>
            <td>Eculizumab (reduces haemolysis, thrombosis risk). Anticoagulation if thrombosis</td>
          </tr>
          <tr>
            <td>Malaria</td>
            <td>Antimalarials (artemisinin-based for <em>P. falciparum</em>). Exchange transfusion if severe</td>
          </tr>
        </table>

        <p><strong>3. Long-term Management:</strong></p>
        <ul>
          <li><strong>Folic acid supplementation:</strong> Chronic haemolysis states (sickle cell, hereditary spherocytosis)</li>
          <li><strong>Monitoring:</strong> Regular FBC, reticulocyte count, bilirubin</li>
          <li><strong>Vaccination:</strong> If splenectomy planned or functional hyposplenism (sickle cell):
            <ul>
              <li>Pneumococcus (PCV13 + PPV23)</li>
              <li>Meningococcus (MenACWY + MenB)</li>
              <li>Haemophilus influenzae type B</li>
              <li>Annual influenza</li>
            </ul>
          </li>
          <li><strong>Antibiotic prophylaxis:</strong> Penicillin V or amoxicillin lifelong post-splenectomy or in sickle cell disease</li>
          <li><strong>Gallstone surveillance:</strong> Chronic haemolysis → pigment stones. Cholecystectomy if symptomatic</li>
          <li><strong>Genetic counseling:</strong> Inherited conditions</li>
          <li><strong>Patient education:</strong> Trigger avoidance (G6PD), infection prevention, when to seek help</li>
        </ul>

        <p><strong>4. Complications to Monitor:</strong></p>
        <ul>
          <li>Gallstones (pigment stones from chronic bilirubin production)</li>
          <li>Folate deficiency</li>
          <li>Iron overload (if multiple transfusions) - monitor ferritin, consider iron chelation</li>
          <li>Aplastic crisis (parvovirus B19 infection)</li>
          <li>Thrombosis (PNH, sickle cell)</li>
          <li>Renal failure (intravascular haemolysis, HUS)</li>
        </ul>
      </div>
    </div>

    <h2>Key Learning Points - Summary</h2>
    <div class="key-points">
      <ul>
        <li><strong>Haemolytic anaemia</strong> is premature RBC destruction. Classified as <strong>inherited (intrinsic RBC defects)</strong> vs <strong>acquired (extrinsic factors)</strong>, and <strong>intravascular</strong> vs <strong>extravascular</strong></li>
        <li><strong>Key laboratory markers:</strong> ↑↑ Reticulocytes (most important), ↑ unconjugated bilirubin, ↑ LDH, ↓ haptoglobin. <strong>Undetectable haptoglobin = intravascular haemolysis</strong></li>
        <li><strong>Blood film is crucial:</strong> Spherocytes (hereditary spherocytosis, AIHA), sickle cells (SCD), schistocytes (MAHA), bite/blister cells (G6PD)</li>
        <li><strong>Direct Antiglobulin Test (DAT/Coombs):</strong> Positive in immune-mediated haemolysis (AIHA, drug-induced). Negative in non-immune causes</li>
        <li><strong>G6PD deficiency:</strong> X-linked, episodic haemolysis triggered by infection/drugs/fava beans. Bite/blister cells. Diagnose with G6PD assay (do AFTER acute episode). Treatment: Stop trigger, avoid in future</li>
        <li><strong>AIHA:</strong> Warm (IgG, 37°C, steroids effective) vs Cold (IgM, 4°C, <strong>steroids NOT effective</strong>, rituximab works)</li>
        <li><strong>MAHA:</strong> Schistocytes on film. Causes include TTP (plasma exchange urgently), HUS (supportive ± eculizumab), DIC, mechanical valves</li>
        <li><strong>TTP vs HUS:</strong> TTP = neuro signs + ADAMTS13 deficiency + adults, urgent plasma exchange. HUS = AKI predominant + children + post-diarrhoea (<em>E. coli</em>)</li>
        <li><strong>Hereditary spherocytosis:</strong> Spherocytes, splenomegaly, osmotic fragility +ve. Splenectomy curative</li>
        <li><strong>General management:</strong> Identify and treat cause, folic acid supplementation, hydration (intravascular haemolysis), transfusion if severe</li>
        <li><strong>Complications:</strong> Gallstones (chronic haemolysis), aplastic crisis (parvovirus B19), folate deficiency, iron overload (multiple transfusions)</li>
        <li><strong>Post-splenectomy/sickle cell:</strong> Lifelong penicillin prophylaxis + vaccinations (pneumococcus, meningococcus, Hib, influenza)</li>
      </ul>
    </div>

    <h2>Case Scenario - Answer</h2>
    <div class="key-points">
      <p><strong>Diagnosis: G6PD Deficiency with Drug-Induced Haemolytic Crisis</strong></p>

      <p><strong>Evidence:</strong></p>
      <ul>
        <li>Mediterranean descent (high prevalence)</li>
        <li>Acute haemolysis triggered by co-trimoxazole (sulfonamide) and infection</li>
        <li>Intravascular haemolysis: Undetectable haptoglobin, haemoglobinuria, very high LDH</li>
        <li>Blood film: Bite cells, blister cells</li>
        <li>DAT negative (excludes AIHA)</li>
        <li>Family history (father with "blood problem" requiring splenectomy - possibly hereditary spherocytosis or G6PD)</li>
      </ul>

      <p><strong>Management:</strong></p>
      <ul>
        <li><strong>STOP co-trimoxazole immediately</strong></li>
        <li>IV hydration (protect kidneys from free haemoglobin)</li>
        <li>Monitor Hb - transfusion if drops <70 g/L or symptomatic</li>
        <li>Folic acid 5mg daily during acute haemolysis</li>
        <li>Confirm diagnosis with <strong>G6PD enzyme assay</strong> in 2-3 months (may be falsely normal now)</li>
        <li><strong>Education:</strong> Provide comprehensive list of drugs and foods to avoid</li>
        <li>Medical alert bracelet</li>
        <li>Screen family members</li>
      </ul>
    </div>

    <h2>Further Learning Resources</h2>
    <ul>
      <li>Practice interpreting blood films: identify spherocytes, schistocytes, sickle cells, bite cells</li>
      <li>Review the pentose phosphate pathway and understand G6PD's role in protecting RBCs from oxidative damage</li>
      <li>Learn the diagnostic algorithm for pancytopenia vs isolated anaemia with reticulocytosis</li>
      <li>Understand ADAMTS13 function and why its deficiency causes TTP</li>
      <li>Review splenectomy vaccination schedules and lifelong antibiotic prophylaxis requirements</li>
      <li>Compare intravascular vs extravascular haemolysis - understand why haptoglobin and haemoglobinuria differ</li>
    </ul>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        }
      }
    }// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          }
        }, 100);
      }
    });
    }
  </script>

</body>
</html>
